Company overview
Basic information
Company name
Ekobetonas, UAB
Company code
300636364
VAT code
LT100002840115
Registered address
Marijampolė, Gamyklų g. 3, LT-68108
Registration date
2007-01-22
Company age: 19 y. 9 mo.
Contact information
Edit data
Phone
Presented as an image – cannot be copied
Email
Presented as an image – cannot be copied
Website
https://ekobetonas.lt
Company manager
For registered members only
Log in
Indicators
Risk factors
Activity
Legal form
Private Limited Liability Company
NACE activity
Manufacture of ready-mixed concrete
Ownership form
Private without foreign capital
UAB "Ekobetonas"
Company code: 300636364
Address: Marijampolė, Gamyklų g. 3, LT-68108
VAT code: LT100002840115
Description
This description was generated by artificial intelligence.
Ekobetonas, UAB (company code 300636364) is an operational private limited liability company registered in 2007. It is a privately owned Lithuanian enterprise, with more than 50% of the authorised capital owned by Lithuanian natural and legal persons and no foreign investor capital. The company is classified as a small business in the national private non-financial companies sector and is governed by a CEO only structure. Its main activity under EVRK code C.23.63.00 is manufacture of ready-mixed concrete. The company is based in Marijampole, at Gamyklu g. 3, in Marijampoles municipality and Marijampole county. In financial year 2025, revenue was €3.89 million, compared with €4.44 million in 2024 and €3.69 million in 2023. Net profit in 2025 was €202.5K, with a profit margin of 5.2%. Equity stood at €761.0K and total assets at €930.5K, while liabilities were €178.9K. The latest staff figures, so far in 2026, show an average of 20 employees and an average monthly wage of €2,156.89. Compared with 2025, wages were up by 3.0%, while employment was unchanged from 2025.
Download a detailed company report
Make confident decisions with all the information about Ekobetonas, UAB. In one document, you will find full financial data, risk and potential assessment, and key Scoris insights.